Shockwave Medical Inc. (SWAV)
(Delayed Data from NSDQ)
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.43 USD
+2.29 (5.57%)
Updated May 3, 2019 04:00 PM ET
After-Market: $43.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Change Healthcare (CHNG) Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal first-quarter 2023 results benefit from solid performance across Software and Analytics, Network Solutions and Enterprise Imaging segments.
LHC Group (LHCG) Q2 Earnings & Revenues Miss Estimates
by Zacks Equity Research
LHC Group's (LHCG) second-quarter results benefit from organic growth in hospice admissions. However, home health admissions decline organically.
Glaukos (GKOS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.
McKesson's (MCK) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2023 results benefit from segmental growth.
Inari Medical (NARI) Q2 Earnings Beat, CEO Transition in 2023
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.
Fresenius Medical's (FMS) Q2 Earnings Miss, Revenues Top
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.
PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) second-quarter results benefit from a solid performance at Discover & Analytics Solutions business.
Shockwave Medical (SWAV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RFG
DexCom (DXCM) Q2 Earnings Match Estimates, Revenues Miss
by Zacks Equity Research
Despite the top line missing estimates, DexCom's (DXCM) second-quarter results reflected strong domestic and international revenue growth.
Baxter (BAX) Q2 Earnings Miss Estimates, Hilrom Adds $715 M
by Zacks Equity Research
Baxter's (BAX) second-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
Surmodics (SRDX) Beats on Q3 Earnings, Revises FY22 View
by Zacks Equity Research
Product sales primarily drive Surmodics' (SRDX) third-quarter top-line growth. However, the company expects softer demand for its products and services in the second half of 2022.
CONMED (CNMD) Down on In-Line Q2 Earnings & Lower 2022 View
by Zacks Equity Research
CONMED's (CNMD) adjusted second-quarter earnings reflect strong segmental performance. However, unfavorable currency movement hurt sales growth. Inflationary or supply chain challenges hurt gross margin.
Integra (IART) Q2 Earnings Top, 2022 Adjusted EPS View Cut
by Zacks Equity Research
Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.
Align Technology (ALGN) Q2 Earnings Lag Estimates, Margins Drop
by Zacks Equity Research
The dull underlying market situation, impacted by macro-economic environmental factors and lingering effects of COVID-19 variants in certain markets, impacts Align Technology's (ALGN) Q2 results.
Boston Scientific (BSX) Q2 Earnings Beat, Margins Decline
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWM
Intuitive Surgical (ISRG) Q2 Earnings Miss, Procedures Recover
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect health demand for procedures despite the resurgence of COVID-19 infections.
Here's Why You Should Hold On to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.
Here's Why You Should Retain Fresenius Medical (FMS) Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Centene (CNC) Divests Unit to Boost Focus on Core Business
by Zacks Equity Research
Centene (CNC) closes the deal to divest its pharmacy business. CNC primarily intends to pursue share repurchases with proceeds received from the transaction.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
Here's Why You Should Buy DENTSPLY SIRONA (XRAY) Stock Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.
Fresenius (FMS) Faces Fraud Accusation From US Government
by Zacks Equity Research
The Department of Justice of the U.S. government files a civil complaint against Fresenius (FMS), accusing it of defrauding Medicare and other healthcare programs by billing for unnecessary procedures.